ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA
Prospective Registry Study to Collect Imaging and Clinical Data on Patients With Aortic Aneurysm Disease Undergoing Serial Monitoring & Pre and Post Endovascular Repair
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This a prospective, multi-center, registry of patients that are being assessed with the ViTAA software. Patients will be enrolled at selected North American centers in the US and Canada. The Registry will enroll patients from the following two populations:
- patients who are scheduled and ultimately receive endovascular infrarenal aortic aneurysm repair (EVAR);
- patients who do not yet qualify for infrarenal aortic aneurysm repair based on anatomic size criteria who are enrolled in a serial monitoring program.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Denis Bilodeau
- Phone Number: 5145728673
- Email: denisbilodeau@vitaamedical.com
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T1Y 6J4
- Recruiting
- UCGY - University of Calgary, Peter Lougheed Center
-
Principal Investigator:
- Paul Petrasek, MD
-
Contact:
- Emi Sanders
- Email: emi.sanders@albertahealthservices.ca
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Recruiting
- UHN - University Health Network - Toronto General Hospital
-
Contact:
- Naomi Eisenberg
- Email: Naomi.Eisenberg@uhn.ca
-
Principal Investigator:
- Thomas Forbes, MD
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 3E4
- Recruiting
- CHUM - Centre Hospitalier de l'Universite de Montreal
-
Principal Investigator:
- Gilles Soulez, MD
-
Contact:
- Jennifer Satterthwaite
- Phone Number: 23483 514 890-8000
- Email: jennifer.satterthwaite.chum@ssss.gouv.qc.ca
-
Contact:
- Casey Bourdeau-Caporuscio, BSc, MSc
- Phone Number: 14756 514-890-8000
- Email: casey.bourdeau-caporuscio.chum@ssss.gouv.qc.ca
-
Montreal, Quebec, Canada, H4A 3J1
- Recruiting
- MUHC - McGill University Health Centre
-
Contact:
- Marie-Amélie Lukaszewski
- Phone Number: 35113 +1 514-934-1934
- Email: marie-amelie.lukaszewski@muhc.mcgill.ca
-
Principal Investigator:
- Kent MacKenzie, MD
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- UAB - University of Alabama in Birmingham Hospital
-
Contact:
- Rebecca St John
- Email: rstjohn@uabmc.edu
-
Principal Investigator:
- Adam Beck, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- MGH - Massachusetts General Hospital Fireman Vascular Center
-
Principal Investigator:
- Matt Eagleton, MD
-
Contact:
- Jamie Attwood, RN
- Email: jlattwood@mgh.harvard.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- UNC - University of North Carolina at Chapel Hill
-
Contact:
- Rebekah Roten
- Email: rebekah_roten@med.unc.edu
-
Principal Investigator:
- Mark Farber, MD
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- University of Washington
-
Principal Investigator:
- Benjamin Starnes, MD
-
Contact:
- Allison Larimore, MSN, RN, CCRN
- Phone Number: 206-744-8257
- Email: alari@uw.edu
-
Contact:
- Sonja Katt
- Phone Number: 206-744-8257
- Email: skatt@uw.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
- Patients who are booked for and then subsequently have undergone endovascular repair.
- Patients with infrarenal aortic aneurysms without indications for repair undergoing serial monitoring.
Description
Inclusion Criteria:
- Patient is aged 18 years or over
- Infrarenal Aortic Aneurysm ≥ 45 mm in diameter.
- Patient meets on-IFU criteria for endovascular reconstruction
Exclusion Criteria:
- Patient has a known or clinically suspected major connective tissue disorder, autoimmune disorder, vasculitis, or aortic dissection.
- Patient has renal failure (defined as dialysis dependent or serum creatinine ≥2.0mg/dL or 175umol/L
- Patients with previous aortic reconstruction in the involved segment.
- Patients receiving oral or parenteral corticosteroid therapy for other unrelated disease. (Excludes inhaled corticosteroids).
- Patient has a sensitivity to contrast imaging agents.
- Patient has aortic dissection.
- Patient has atrial fibrillation.
- Patient has arrhythmia.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients who are booked for and then subsequently have undergone endovascular repair.
Patients who are scheduled and ultimately receive on-IFU endovascular infrarenal aortic aneurysm repair (EVAR)
|
Imaging Analysis Software
|
|
Patients with infrarenal AA without indications for repair undergoing serial monitoring
Patients who do not yet qualify for the aortic aneurysm repair who are enrolled in a serial monitoring program
|
Imaging Analysis Software
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite of aneurysm rupture or critical growth.
Time Frame: 6 months
|
|
6 months
|
|
Composite of aneurysm rupture or critical growth.
Time Frame: 1 year
|
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CHUM Ancillary Ultrasound Study
Time Frame: 6 months
|
For patients recruited at the CHUM:
|
6 months
|
|
CHUM Ancillary Ultrasound Study
Time Frame: 1 year
|
For patients recruited at the CHUM:
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mark Farber, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIP-ViTAA-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.